anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Tumors were observed in the urinary bladder of male rats in the two-year carcinogenicity study [seeNonclinical Toxicology (13.1)]. In two 3-year trials in whichpioglitazonetablets were compared to placebo orglyburide, there were 16/3656 (0.44%) reports of bladder cancer in patients takingpioglitazonetablets compared to 5/3679 (0.14%) in patients not takingpioglitazonetablets. After excluding patients in whom exposure to study drug was less than one year at the time of diagnosis of bladder cancer, there were six (0.16%) cases onpioglitazonetablets and two (0.05%) cases on placebo.

A five-year interim report of an ongoing 10-year observational cohort study found a non-significant increase in the risk for bladder cancer in subjects ever exposed topioglitazonetablets, compared to subjects never exposed topioglitazonetablets (HR 1.2 [95% CI 0.9 – 1.5]). Compared to never exposure, a duration ofpioglitazonetablets therapy longer than 12 months was associated with an increase in risk (HR 1.4 [95% CI 0.9 – 2.1]), which reached statistical significance after more than 24 months ofpioglitazonetablets use (HR 1.4 [95% CI 1.03 – 2.0]). Interim results from this study suggested that takingpioglitazonetablets longer than 12 months increased the relative risk of developing bladder cancer in any given year by 40% which equates to an absolute increase of three cases in 10,000 (from approximately seven in 10,000 [withoutpioglitazonetablets] to approximately 10 in 10,000 [withpioglitazonetablets]).

There are insufficient data to determine whetherpioglitazoneis a tumor promoter for urinary bladder tumors. Consequently,pioglitazonetablets should not be used in patients with active bladder cancer and the benefits ofglycemiccontrol versus unknown risks for cancer recurrence withpioglitazonetablets should be considered in patients with a prior history of bladder cancer.
PURPOSE:To enable the automatic prepn. of a dialyzate of a prescribed concn. by constituting the dissolving device in such a manner that the vessels encapsulated with fixed amts. of two kinds of solid dialysis drugs are arranged by each one pair on the concentrical circles parting at prescribed distances in a radial direction and that diluting water is supplied at a fixed rate into the respective vessels by successively transferring these vessels. CONSTITUTION:Two kinds of the vessels 10, 12 in which the powder or granular solid dialysis drugs are encapsulated are held in a turn table 14 and thereafter, the turn table 14 is rotated to position the respective vessels 10, 12 to a prescribed position P1. Vessel connecting means 28, 30 are then liquidtightly set in the mouth parts of the respective vessels 10, 12 and thereafter, stop valves 48, 50 are opened and the fixed volume of the diluting water is supplied from fixed rate water feeding means 44, 46 into dissolving tanks 32, 34. Pump devices 40, 42 are then driven to supply the diluting water in the dissolving tanks 32, 34 into the respective vessels 10, 12. While the solid dialysis drugs are thus dissolved in the diluting water, the solid dialysis drugs are discharged into the dissolving tanks 32, 34 and are stored as solns. These solns. are thereafter supplied to a mixing and dissolving tank 60. The prepn. of the dyalizate is thus ended.
OBJECTIVE: Src homology phosphotyrosin phosphatase 2 (SHP2) has been implicated in the progression of several cancer types. However, its function in endometrial cancer (EC) remains unclear. Here, we report that the ten-eleven translocation 3 (TET3)-mediated DNA demethylation modification is responsible for the oncogenic role of SHP2 in EC and explore the detailed mechanism.
METHODS: The transcriptomic differences between EC tissues and control tissues were analyzed using bioinformatics tools, followed by protein-protein interaction network establishment. EC cells were treated with shRNA targeting SHP2 alone or in combination with isoprocurcumenol, an epidermal growth factor receptor (EGFR) signaling activator. The cell biological behavior was examined using cell counting kit-8, colony formation, flow cytometry, scratch assay, and transwell assays, and the median inhibition concentration values to medroxyprogesterone acetate/gefitinib were calculated. The binding of TET3 to the SHP2 promoter was verified. EC cells with TET3 knockdown and combined with SHP2 overexpression were selected to construct tumor xenografts in mice.
RESULTS: TET3 and SHP2 were overexpressed in EC cells. TET3 bound to the SHP2 promoter, thereby increasing the DNA hydroxymethylation modification and activating SHP2 to induce the EGFR/extracellular signal-regulated kinase (ERK) pathway. Knockdown of TET3 or SHP2 inhibited EC cell malignant aggressiveness and impaired the EGFR/ERK pathway. Silencing of TET3 inhibited the tumorigenic capacity of EC cells, and ectopic expression of SHP2 or isoprocurcumenol reversed the inhibitory effect of TET3 knockdown on the biological activity of EC cells.
CONCLUSION: TET3 promoted the DNA demethylation modification in the SHP2 promoter and activated SHP2, thus activating the EGFR/ERK pathway and leading to EC progression.
A new class of antibodies having specificity for glycoproteins are described. The antibodies are shown to bind sensitively and specifically to mannosylated proteins, such as proteins produced by fungi. Assays using these anti-glycoprotein antibodies for monitoring the presence of glycoproteins in a sample are provided. Such methods can be used to monitor methods for production and/or purification of desired polypeptides, which may be used to modify process parameters to modify (e.g., decrease or increase) the amount of glycosylated polypeptide produced and/or present in the purified product. Also provided are methods of using the subject antibodies for detecting the level of expression and secretion of a polypeptide, and methods of using the subject antibodies to purify or deplete a glycoprotein from a sample. In exemplary embodiments, the desired polypeptide may be a multi-subunit protein, such as an antibody, which may be produced in a yeast, such as Pichia pastoris.
After the surgery, the patient will be placed in the study provided semiconductor element interwoven Incrediwear Leg Sleeve from the ankle to the thigh and the Incrediwear sock, on the operative leg, and a thigh high compression hose on the non operative leg, worn 23 hours per day. At day 31 patient will wear the leg sleeve at night and be placed in the Incrediwear Knee Sleeve.
The National Heart, Lung, and Blood Institute convened a virtual workshop in September 2022 to discuss "Optimal Instruments for Measurement of Diet, Physical Activity, and Sleep." This report summarizes the proceedings, identifying current research gaps and future directions for measuring different lifestyle behaviors in adult population-based studies. Key discussions centered on integrating report-based methods, like questionnaires, with device-based assessments, including wearables and physiological measures such as biomarkers and omics to enhance self-reported metrics and better understand the underlying biologic mechanisms of chronic diseases. Emphasis was placed on the need for data harmonization, including the adoption of standard terminology, reproducible metrics, and accessible raw data, to enhance the analysis through artificial intelligence and machine learning techniques. The workshop highlighted the importance of standardizing procedures for integrated behavioral phenotypes using time-series data. These efforts aim to refine data accuracy and comparability across studies and populations, thereby advancing our understanding of lifestyle behaviors and their impact on chronic disease outcomes over the life course.
Patients with positive sentinel node(s) by PCR analysis are randomized to one of three treatment arms. Patients undergo observation. Patients are followed every 3 months for 2 years, every 4 months for 1 year, every 6 months for 2 years, and then annually thereafter.
The invention discloses a novel multifunctional Siamese bacillus and preparation and application of a bioactive product thereof. Siamenobacillus (Bacillus siamensis) SCSIO 05746, deposit number: CGMCC No. 13640. The bacterium has the ability to produce bacilacenes, bacillbactins, bacillomycin, bacilysin, butirosin, difficilins, fengycins, macrolactins, surfactin, terpenes, PKS III and various ribosomal peptide compounds. Can be used as a biological control microbial inoculum for application. The strain can also be used for preparing linear siderophores linbacetin A-B (1-2) and siambaptin A (3) and preparing other types of products with biological activities such as antibacterial, antifungal and cytotoxic activity, bacillus aenes, bacillus bactins, bacillus mycin, fengycins, macrolactins and surfactin and the like. And the prepared compounds have application prospects in the fields of agriculture, food, medicine and the like.
The present invention provides a coenzyme Q10 clear preparation which is added into skin caring articles and a preparation method thereof, and belongs to the technical field of personal caring article preparation. The coenzyme Q10 clear preparation comprises the following components: coenzyme Q10, emulsifier mixture, pH regulator, stabilizer and water. The particle size of microemulsion of the coenzyme Q10 is less than 150nm. The microemulsion solution is yellow clear water solution. Furthermore the coenzyme Q10 clear preparation has the following advantages: low viscosity, better fluidity, and high stability. The coenzyme Q10 clear microemulsion preparation prepared according to the invention overcomes the following defects in coenzyme Q10: low water solubility, low oil solubility, and high difficulty of being added into personal caring article. Simultaneously the preparation performs antioxidation and anti-aging biological activity on the skin. The process for preparing the personal nursing product which comprises the coenzyme Q10 is simplified. A novel dosage form is provided for the application of the coenzyme Q10 on the aspect of personal nursing product.
Background: The gut microbiome is established early in life and plays an important role in developing the immune system and metabolism. Infants born prematurely (before 37-weeks gestation) account for 1 in 10 births worldwide and are especially vulnerable to serious microbiome-mediated illnesses such as necrotizing enterocolitis and metabolic diseases. Breastfeeding is the most important factor shaping the infant gut microbiome, providing human milk oligosaccharides (HMOs) that serve as prebiotics for beneficial gut bacteria. Donor human milk (DHM) is considered the best alternative when mothers own milk (MOM) is not available. HMO profiles are highly variable between mothers and there is currently no "matching" process to optimize pairing of DHM and recipient infants. The strongest factor influencing HMO composition is maternal secretor status, determined by the expression of a specific gene (α-1, 2-fucosyltransferase-2). About 20% of Caucasians are non-secretors and researchers do not know the impact of feeding DHM from secretor donors to infants of non-secretor mothers. In this study, investigators aim to explore if matching DHM based on maternal secretor status impacts the development of the gut microbiome in preterm infants.

Method: Investigators will use a pilot, randomized, controlled trial to compare three groups of preterm infants (\<34 weeks gestation): 1) infants receiving DHM matched to their mother's secretor status, 2) infants receiving standard issue (i.e. unmatched) DHM, and 3) infants who do not require DHM because they are exclusively receiving MOM. Mothers \<34 weeks gestation admitted to antenatal units and the labour and delivery units will be screened for eligibility. Enrolled mothers will be randomized to either the intervention (n=30; matched DHM) or control group (n=30; standard unmatched DHM). Infants of mothers assigned to the intervention group will receive "matched" DHM based on maternal secretor status, determined after randomization. Infant fecal samples will be collected weekly from soiled diapers until discontinuation of DHM or discharge/transfer from the unit. Samples of MOM and DHM will also be collected to analyze milk for HMO and nutrient content. Microbial DNA will be analyzed using 16S sequencing. Additionally, for a subset of samples selected based on 16S results, investigators will perform shotgun metagenomics to identify microbial population structures and functional capacity. Microbial composition from intervention (matched DHM), control (unmatched DHM) and reference (exclusive MOM) groups will be compared to determine differences in microbial diversity and taxonomy.

Impact on healthcare: If promising, investigators would like to examine this phenomenon in a much larger cohort of preterm infants from NICUs across Canada. This research could revolutionize how milk banks and neonatal intensive care units provide DHM to preterm infants. Finally, this research will expand on understanding of the prebiotic effects of HMOs on infant microbiome and may inform future prebiotic/probiotic supplementation regimens.
A model-assisted annotating system is operable to receive a first set of annotation data for a first set of medical scans from a set of client devices. A computer vision model is trained by utilizing first set of medical scans and the first set of annotation data. A second set of annotation data for a second set of medical scans is generated by utilizing the computer vision model. The second set of medical scans and the second set of annotation data is transmitted to the set of client devices, and a set of additional annotation data is received in response. An updated computer vision model is generated by utilizing the set of additional annotation data. A third set of annotation data is generated for a third set of medical scans by utilizing the updated computer vision model for transmission to the set of client devices for display.
This is a prospective observational study. 150 subjects with the admission diagnosis of neurological haemorrhage (e.g. subarachnoid haemorrhage, intracerebral haemorrhage etc), admitted to SICU of National University Hospital, Singapore, who are expected to stay for more than 48 hours, will be recruited and enrolled. No adverse events are expected as a result of this study as patients do not deviate from the current standard of care. Frequency of blood sampling will be stipulated at day 1/2/3/4/5 to draw clinical relevance. An additional 0.5 tablespoonful (7.7ml) of blood will be taken daily from each subject as well as residual blood from routine laboratory test blood samples. In total, an additional volume of 2.5 tablespoonful (38.5ml) of blood will be collected from each subject over a period of 5 days. Residual blood refers to any leftover blood samples collected for routine laboratory tests which will be shared and used to carry out additional blood tests. All ICU patients will have arterial lines inserted as part of routine care, so there will not be pain from the blood sampling. In the current study, measurements will be made on the routine laboratory haematology, coagulation and immunoassay analyzers. Research blood parameters that are not usually reported as indicated in the background section will be used for the correlation and association analysis to sepsis. In addition, the study team will also be collecting clinical and demographic data of recruited subjects from medical records for purposes of this study.
The patients are thoroughly informed verbally and in writing how to eat according to traditional IBS dietary advices. The diet imply adapting to regular dietary habit with meals 6 times a day, no to big meals, to chew food thoroughly, to peel fruits and vegetables, no carbonated beverages, no chewing gum, no soft drinks, no sugar-free candies, or cookies. Reduce spicy foods, coffee, alcohol, onion, pulses, and fatty foods. Keep strictly to the dietary advice for 4 weeks.
FIELD: medicine. SUBSTANCE: method involves the use of immunomodulating agents at low titer of blood specific antibodies based on belong of antibodies to classes of immunoglobulins at subacute, obliterated, unapparent, slow or chronic infection course which are given every day or each other day. These agents are combined with oral and/or rectal administration of bifidumbacterin preparations and/or acylact. Then after elevation of blood antibody titer and based on belong of antibodies to classes of immunoglobulins antibiotic therapy is prescribed for 5-14 days. At the end of treatment immunomodulating agents are used again in combination with oral and/or rectal administration of bifidumbacterin and/or acylact administration. Suppositories containing recombinant α 2 -interferon and immunoglobulins at effective amount, suppositories or suspension with bifidumbacterin and suppositories or suspension with acylact are administrated successively for 5-10 days in infections of female genital organs by intravaginal route. Method ensures to achieve the recovery of patients with sluggish infections using sparing immunocorrection ways. EFFECT: improved method of treatment. 3 cl, 3 ex
Participants will receive screening, testing, immunization, and risk reduction. Screening and testing will take place at study entry, immunization will occur at entry and after 3 and 6 months, and risk reduction will take place at study entry and after 3 and 6 months.
PROBLEM TO BE SOLVED: To stably obtain a cosmetic material for makeup excellent in soft touch in high efficiency by using a prescribed amount of powder having prescribed creep characteristics. SOLUTION: This cosmetic material contains powder having value a of 5 or less or value b/a of 0.6 or less on the measurement value of the stress of powdered simple substance moldings in an amount of more than 30wt.%. Particularly it is preferable to contain more than 35wt.%, especially more than 40wt.%. This powder is particularly preferable to have a value of more than 3 and b/a value of 0.6 or less. As this powder, e.g. polyorganopolysiloxane elastomer powder, boron nitride, fired sericite, synthetic phlogopite and phlogopite are illustrated. This cosmetic material for makeup is producible by using both methods of dry molding and wet molding. As this cosmetic material for makeup, toilet powder, powders for face, foundation, rouge, cheek rouge, eyeliner and mascara are illustrated.
PURPOSE: To provide a cross linking agent-bonded carrier excellent in shelf life by providing a diol structure or polyol structure in the terminal area of the cross linking agent bonded to carrier protein, and prepare an immunogen in a short time by use of this cross linking agent-bonded carrier. CONSTITUTION: Bisepoxide is reacted with carrier protein as a cross linking agent to form an epoxidized carrier protein. The epoxy group in the terminal part which is not reacted with the carrier protein of the cross linking agent is changed to a stable diol structure. Thus, it can be stored for a long period. It is treated with periodic acid at the reaction with hapten to convert the diol group into an aldehyde group. After the excessive periodic acid is then removed, it is reacted with the hapten having an amino group to form a Schiff's base, whereby an immunogen can be easily formed.
For this study, 56 volunteers who had an equal allocation rate between the groups (G1-control and G2-experimental) were selected for this study. Both gels act in the same way, the difference between them is the concentration. In both groups, the different desensitizing gels were applied to the vestibular surface of the anterior superior teeth with the aid of a tray, remaining in position according to the time specified by the manufacturers. In the control group, a gel based on 5% potassium nitrate and 2% sodium fluoride was used, while in the experimental group, the gel was based on 3% potassium nitrate and 0.25% sodium fluoride. After removal of the desensitizing gel, both groups were subjected to bleaching with 40% hydrogen peroxide gel for 40 minutes. Patients recorded an occurrence or not of dental sensitivity (SD) in a sensitivity diary for 48 hours. A Verbal Evaluation Scale (VRS) and a Visual Analogue Scale (VAS) were used for pain assessment. The values were organized into two categories: percentage of patients who presented SD at some time of treatment (absolute risk of sensitivity) and SD intensity. To evaluate the color before the first bleaching session, and after 7, 14 and 28 days, two methods were used: objective evaluation using the spectrophotometer and subjective evaluation using two color scales: Vita Classical and Vita Bleachedguide 3D-MASTER. An analysis of the data followed the intent-to-treat protocol and involved all randomly allocated participants. The absolute risk of SD was compared using Fisher's exact test (α = 5%). The Mann-Whitney test was used to compare the intensity of SD.

Student's t test was used to compare the color change. The level of significance adopted in all tests was 5%.
PAH is characterized by a progressive increase in pulmonary arterial pressure (PAP) and in pulmonary vascular resistance (PVR) potentially leading to right heart failure and death. Current PAH-specific therapeutic options include treatments that target the three pathways (endothelin, nitric oxide, and prostacyclin pathways). While combination treatment is common, FDC pills or tablets that combine two or more PAH-specific therapies are not available, thereby requiring participants to take multiple pills/tablets daily. An FDC is an attractive option for PAH participants because it simplifies the treatment regimen by combining two therapies (which would otherwise involve a total of three tablets: one macitentan 10 mg tablet and two tadalafil 20 mg tablets) into a single tablet. Macitentan is an orally active, non-peptide, potent dual endothelin receptor A and B antagonist. Tadalafil is a selective inhibitor of phosphodiesterase type-5 (PDE-5), the enzyme responsible for the degradation of cyclic guanosine monophosphate (cGMP). This study comprises the following consecutive periods: Screening period (lasts up to 30 days), Double-blind treatment period (consists of the titration phase \[the first 2 weeks\] and the maintenance phase \[Week 3 through Week 16\]), Open-label treatment period, End-of-Treatment (EOT), Safety follow-up (S-FU) period, and End of Study (EOS). The total study duration for a participant will be up to 30 months. Study assessments like physical examinations, vital signs, right heart catheterization, 6-minute walk test will be performed. Safety will be assessed throughout the study.